The neplanocin A analogs, 3-deazaneplanocin A, 9-(trans-2',trans-3'-dihydroxycyclopent-4'-enyl)adenine (DHCA), and 9-(trans-2',trans-3'-dihydroxycyclopent-4'-enyl)-3-deazaadenine (DHCDA), all potent inhibitors of S-adenosylhomocysteine (AdoHcy) hydrolase, were studied for their broad-spectrum antiviral potential. 3-Deazaneplanocin A, DHCA, and DHCDA proved specifically effective against vesicular stomatitis virus, vaccinia virus, parainfluenza virus, reovirus, and rotavirus. Their selectivity was greater than that of neplanocin A, particularly against vesicular stomatitis virus and rotavirus. As could be expected from adenosine analogs that are directly targeted at AdoHcy hydrolase, 3-deazaneplanocin A, DHCA, and DHCDA were fully active in adenosine kinase-deficient cells, implying that their activity did not depend on phosphorylation by adenosine kinase. None of the AdoHcy hydrolase inhibitors showed selective activity against human immunodeficiency virus (type 1). 3-Deazaneplanocin A at a dose of 0.5 mg/kg per day conferred marked protection against a lethal infection of newborn mice with vesicular stomatitis virus.
Neplanocin A is a potent antiviral agent active against a broad spectrum of viruses belonging to the Poxviridae, Rhabdoviridae, Paramyxoviridae, and Reoviridae (6) . It is particularly effective against vaccinia virus, vesicular stomatitis virus, parainfluenza virus, measles virus, reovirus (6) , and human rotavirus (20) . Neplanocin A is a potent inhibitor of S-adenosylhomocysteine (AdoHcy) hydrolase, a key enzyme in transmethylation reactions depending on S-adenosylmethionine as the methyl donor (2) . As such, transmethylation reactions play an important role in the maturation (e.g., 5' capping) of viral mRNA, and AdoHcy hydrolase has been considered to be an important target enzyme for broad-spectrum antiviral agents (7) . In fact, a close correlation has been found between the antiviral effects of a series of adenosine analogs, including neplanocin A, and their inhibitory effects on AdoHcy hydrolase (4, 9) .
Although antivirally active at concentrations which are well below its toxicity threshold for the host cells (6) , neplanocin A is definitely cytotoxic for a number of tumor cells (18, 24) . This cytotoxicity may be attributed to the fact that the compound is readily phosphorylated to its triphosphate (1, 24) , which then interferes with host-cell RNA synthesis (18) . Neplanocin A triphosphate could be further metabolized to S-neplanocylmethionine (14, 19) , and this metabolite may also play an important role in the cytotoxic action of the compound (14) . If the hypothesis is correct that the antiviral action of neplanocin A is due to an inhibitory effect of the compound per se on AdoHcy hydrolase, whereas its cytotoxic action depends upon phosphorylation to the corresponding triphosphate, it should be possible to design neplanocin A analogs that are endowed with antiviral properties while lacking cytotoxicity, thus achieving a better therapeutic index than that of neplanocin A itself.
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For this reason, 3-deazaneplanocin A and the "decapitated" analogs of neplanocin A and 3-deazaneplanocin A, referred to as DHCA [9-(trans-2',trans-3'-dihydroxycyclopent-4'-enyl)adenine] and DHCDA [9-(trans-2',trans-3'-dihydroxycyclopent-4'-enyl)-3-deazaadenine], were synthesized (3, 15, 22) . Both DHCA and DHCDA were indeed more selective in their activity against vaccinia virus than neplanocin A was (16) . In the initial study, the activity against only one virus (vaccinia) was determined and 3-deazaneplanocin A was not included for comparison. We have now extended these studies to a broad range of DNA and RNA viruses. In addition to DHCA, DHCDA, and neplanocin A, we included in our investigation 3-deazaneplanocin A, which is also assumed to be a potent inhibitor of AdoHcy hydrolase but with a lower degree of cytotoxicity than neplanocin A (13, 15) . The structural formulae of the compounds are depicted in Fig. 1 . The compounds were examined for both antiviral and antimetabolic activities in a variety of cell systems. The therapeutic potential of these compounds was also assessed in vivo by using newborn mice infected with a lethal dose of vesicular stomatitis virus. Inhibition of rotavirus replication. Virus yield was measured as described previously (20) , and the antiviral activity of the compounds was expressed as the concentration required to achieve a 90% reduction in the 24-h virus yield.
MATERIALS AND METHODS
Inhibition of HIV replication. The method of the antiretroviral assays has been described previously (23 Cytotoxicity. Cytotoxicity measurements were based on the following parameters: (i) alteration of normal cell morphology, (ii) inhibition of host-cell protein synthesis, and (iii) reduction in the number of viable cells. To evaluate cell morphology (i), confluent cell cultures which had not been infected but were treated with various concentrations of the test compounds were incubated in parallel with the virusinfected cell cultures and examined microscopically at the same time as viral cytopathogenicity was recorded for the virus-infected cell cultures. A disruption of the cell monolayers, e.g., rounding up or detachment of the cells, was considered to be evidence for cytotoxicity. To determine host-cell protein synthesis (ii), the cells were seeded in 96-well microtest plates (Falcon; Becton Dickinson and Co., Lincoln Park, N.J.) at a density of 20,000 cells per well. After 24 h of incubation in a humidified, C02-controlled atmosphere at 37°C, the cells were refed with fresh Eagle minimum essential medium containing 3% fetal calf serum and the appropriate concentration of the test compound. After 72 h of incubation at 37°C, the cells were pulse-labeled for 3 h with L-[4,5-3H]leucine (64 Ci/mmol; 0.5 ,uCi per well) (Amersham, Buckinghamshire, England). After the pulselabel period, the cells were washed with PBS and fixed with methanol. The proteins were precipitated with 10% trichloroacetic acid, and the trichloroacetic acid pellet was solubilized overnight with 1 N NaOH. The solubilized samples were then transferred to scintillation vials and, upon addition of scintillation fluid (Instafluor and Soluene; Packard Instruments, Groningen, The Netherlands), analyzed for radioactivity. Inhibition of the radioactivity counts by 50% was taken as the endpoint for cytotoxicity. To determine cell viability (iii), the cells were enumerated by a trypan blue dye exclusion assay (20) , and the minimum cytotoxic concentration was defined as the concentration of test compound required to cause a 50% reduction in cell number (after 72 h 
RESULTS
When examined for its activity against herpes simplex virus, vaccinia virus, and vesicular stomatitis virus in PRK cells (Table 1) , neplanocin A showed 50% effective concentrations that were comparable to those reported previously (6) . The novel neplanocin A analogs, 3-deazaneplanocin A, DHCA, and DHCDA, were inhibitory to vaccinia virus and vesicular stomatitis virus at concentrations which were only slightly higher than the 50% effective concentration of neplanocin A. In contrast to neplanocin A, its new congeners were much less toxic to host-cells (based on inhibition of host-cell protein synthesis) ( Table 1) . The new neplanocin A analogs were virtually inactive against herpes simplex virus type 1 or 2, and, in this sense, they behaved like C-c3Ado (11) (included as the reference compound) and other adenosine analogs which have been previously recognized as AdoHcy hydrolase inhibitors (7) .
In HeLa cells, as in PRK cells, 3-deazaneplanocin A, DHCA, and DHCDA inhibited the replication of vesicular stomatitis virus at a concentration that was well below their cytotoxicity threshold, whether based on cell morphology or cellular protein synthesis (Table 2) . However, the compounds were much less active in HeLa cells than in PRK cells. As could be expected from AdoHcy hydrolase inhibitors (7), neither 3-deazaneplanocin A, DHCA, nor DHCDA was inhibitory to the (+)RNA viruses poliovirus (Table 2), coxsackievirus (Tables 2 and 3) , and Sindbis and Semliki Forest viruses (Table 3 ). However, they were markedly active against parainfluenza virus, a (-)RNA virus, and reovirus, a double-stranded (+)RNA virus ( achieved at concentrations which were only slightly below the cytotoxicity threshold. When neplanocin A and its congeners were examined for their inhibitory effects on the proliferation of PRK, HeLa, and Vero cells in their exponential growth phase, neplanocin A and 3-deazaneplanocin A were about equally inhibitory to PRK and HeLa cell growth, whereas 3-deazaneplanocin A was about fivefold more inhibitory to Vero cell growth ( Table 4) . Irrespective of the nature of the cells (Vero, HeLa, or PRK), the decapitated neplanocins DHCA and DHCDA were 10-to 100-fold less inhibitory than the parent compounds were (Table 4) , which is consistent with the results reported previously for L-929 cells (16) .
Among the double-stranded RNA viruses, rotaviruses are particularly sensitive to the inhibitory effects of AdoHcy hydrolase inhibitors (7, 20) . This has now been confirmed for C-c3Ado and neplanocin A (Table 5 ); in agreement with earlier findings (20) , these compounds inhibited rotavirus replication at a concentration which was almost 100-fold below their cytotoxicity threshold. Also, 3-deazaneplanocin A, DHCA, and DHCDA proved inhibitory to rotavirus replication at a concentration that was at least 2 orders of magnitude lower than the cytotoxic concentration (Table 5) . 3-Deazaneplanocin A inhibited rotavirus replication at a concentration of 0.04 ,ug/ml, while not being toxic up to a concentration of 400 ,ug/ml, thus achieving a selectivity index of 10,000, the highest selectivity index ever reported for a rotavirus inhibitor.
When evaluated for their inhibitory effects on the replication of HIV-1 in MT-4 cells, none of the compounds listed in Table 6 (i.e., neplanocin A, 3-deazaneplanocin A, DHCA, DHCDA, and C-c3Ado) proved effective at nontoxic concentrations. In fact, neplanocin A and 3-deazaneplanocin A were highly toxic for MT-4 cells (50% cytotoxic doses, 0.016 and 0.025 ,ug/ml, respectively).
If the antiviral effects of neplanocin A and its congeners are mediated by inhibition of AdoHcy hydrolase, the agents do not need to be phosphorylated by AK to achieve their antiviral activity, and, therefore, they may be expected to be antivirally active in AK-cells. A paired AK+-AK-cell system (5) was established to determine the role of AK in the antiviral activity of the adenosine analogs. As shown in Table 7 , neplanocin A, 3-deazaneplanocin A, DHCA, and DHCDA were fully active against vaccinia virus and vesicular stomatitis virus in AK-cells and their 50% effective doses were equal to or only slightly higher than those recorded in AK' cells. In contrast, various other adenosine analogs such as tubercidin, xylotubercidin, sangivamycin, toyocamycin, and cordycepin, which are assumed to act primarily as their phosphorylated products and thus depend on AK for their metabolic conversion, were significantly less active in AK-than AK' cells. This differential activity was particularly striking for tubercidin, which was inhibitory to vaccinia virus and vesicular stomatitis virus in AK-cells at a concentration that was more than 1,000-fold higher than that required to inhibit the same viruses in AK' cells ( Table   7) .
The role of AK in the biological activity of the adenosine analogs was further explored by direct comparison of their 50% inhibitory doses (ID50s) for the growth of AK' and AK-cells. In all cases, the ID50 for AK-cell growth was higher than the ID50 for AK' cell growth (Table 8 ), but, while the ratio of the ID50 for AK-cell growth to the ID50 for AK' cell growth did not exceed 1 order of magnitude for the neplanocin A congeners, it went up to 3 orders of magnitude for tubercidin, toyocamycin, and cordycepin. Again, these results point to the need for phosphorylation of the latter adenosine analogs by AK, whereas such phosphorylation is of lesser importance for the biological activity of the neplanocin A analogs. Because of their potency against vesicular stomatitis virus in cell culture (Table 1) , the neplanocin A analogs were further investigated for their activity against a lethal vesicular stomatitis virus infection in mice, i.e., newborn mice inoculated subcutaneously with vesicular stomatitis virus. In this model (10), neplanocin A does not offer any protection (6). 3-Deazaneplanocin A, however, conferred a highly significant reduction in the mortality rate when administered as a single dose of 0.5 or 2.5 mg/kg per day (1 h postinfection) or repeated doses of 0.5 mg/kg per day (1 h and 2, 3, and 4 days postinfection) (Fig. 2) . At lower doses (0.1 mg/kg per day) and higher doses (2.5 mg/kg per day [five times], 10 mg/kg per day, and 50 mg/kg per day), it was not protective (Table 9) . At these higher doses, 3-deazaneplanocin A was also toxic to the mice (data not shown). DHCA offered some protective activity, but only at a dose of 0.5 mg/kg per day, given singly or repeatedly (Table 9) . At a dose of 2.5 mg/kg per day (or higher) it was toxic (data not shown). For DHCDA there was only a hint of activity, if administered at a dose of 0.5 mg/kg per day (Table 9 ). Cordycepin 0.7 >200 0.1 (tox) >200 " Required to inhibit virus-induced cytopathogenicity by 50%. The values are averages for two to three experiments. Where the indicated value is followed by (tox), microscopically visible cytotoxicity was observed at the minimum (antivirally) effective concentration. (13, 16) . This expectation was fulfilled in that 3-deazaneplanocin A, DHCA, and DHCDA were indeed more selective in their antiviral action than neplanocin A was. This higher selectivity is particularly evident when the concentrations required for inhibition of vesicular stomatitis virus replication are compared with those that are needed to inhibit cellular protein synthesis (Tables 1 and 2 ). On the basis of these data, 3-deazaneplanocin A, DHCA, and DHCDA would attain a selectivity index (ratio of the minimum cytotoxic concentration to the 50% effective dose) of 3 orders of magnitude (Table 1) . Even more remarkable is the selectivity of 3-deazaneplanocin A against rotavirus, for which it achieves a selectivity index of 4 orders of magnitude (Table 5) . The antiviral activity spectrum of 3-deazaneplanocin A, DHCA, and DHCDA is similar to that of neplanocin A (6), C-c3Ado (11) , and the other adenosine analogs that have been previously recognized as AdoHcy hydrolase inhibitors (7) . This spectrum includes, in addition to the viruses that were found to be susceptible to the neplanocin A analogs in the present study (vaccinia, vesicular stomatitis, parainfluenza, reo-, and rotaviruses), African swine fever, measles, rabies, and several plant viruses. It seems imperative to further examine 3-deazaneplanocin A, DHCA, and DHCDA for their activity against these viruses.
In contrast, neither neplanocin A nor 3-deazaneplanocin A, DHCA, DHCDA, or C-c3Ado caused a selective inhibition of HIV replication in cells. Yet, treatment of MT-4 cells with neplanocin A (1 to 10 ,uM) increased intracellular AdoHcy levels 5-to 10-fold and reduced
AdoHcy hydrolase activity to 1 to 2% (data not shown).
Also, DHCA, DHCDA, and C-c3Ado are assumed to achieve their antiviral and anticellular effects through inhibition of AdoHcy hydrolase. Since none of these compounds proved to be active against HIV, one may infer that the replication of HIV, unlike the reduction of the other viruses mentioned above, is not influenced by an increase in AdoHcy levels. Thus, AdoHcy hydrolase does not appear to be an appropriate target for the design of anti-HIV agents. 3-Deazaneplanocin A, DHCA, and DHCDA are potent inhibitors of AdoHcy hydrolase (13, 17, 22) , and their antiviral effects can be attributed to inhibition of the enzyme. With a series of four compounds [(S)-9-(2,3-dihydroxypropyl)adenine, (RS)-3-adenin-9-yl-2-hydroxypropanoic acid, C-c3Ado, and neplanocin A], a close correlation (r = 0.986) was found between antiviral potency (against vesicular stomatitis virus) and inhibitory effects on (bovine liver) AdoHcy hydrolase (9) . With an extended number of compounds, now also including adenosine dialdehyde and 3-deazaneplanocin A, an even better correlation (r = 0.993) was found between potency against vaccinia virus and inhibitory effects on L-929 cell AdoHcy hydrolase (4). This close correlation points to AdoHcy hydrolase as the target for the antiviral action of these adenosine analogs.
From a mechanistic viewpoint, the present results reinforce the concept that neplanocin A and its congeners owe their antiviral activity to inhibition of AdoHcy hydrolase. The fact that the decapitated analogs DHCA and DHCDA, which lack the 4'-hydroxymethyl group that would otherwise make them substrates for AK, were more selective in their antiviral action than neplanocin A was clearly indicates that the compounds are active per se and do not have to be phosphorylated to acquire antiviral activity. Also, the neplanocin A analogs did not lose much of their antiviral or cytostatic potential in AK cells relative to the corresponding AK' cells (Tables 7 and 8 ), which again indicates that any phosphorylation by the AK would be superfluous for their antiviral or cytostatic action.
From a therapeutic viewpoint, it is evident that 3-deazaneplanocin A, DHCA, and DHCDA should be further pursued for their in vivo efficacy in the appropriate animal models. In one such model, in which mortality of newborn mice was monitored after a lethal infection with vesicular stomatitis virus, 3-deazaneplanocin A provided a highly significant protection (Fig. 2) over a narrow dosage range (0.5 to 2.5 mg/kg per day) ( Table 9 ). With DHCA and DHCDA, little efficacy was noted at the subtoxic dose (0.5 mg/kg per day). To obtain a better insight into the clinical potential of the compounds, these studies should be extended to other treatment regimens (e.g., treatment started late postinfection) and other animal models (e.g., rota and rabies).
